S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:MESO

Mesoblast (MESO) Stock Price, News & Analysis

$5.01
+1.52 (+43.55%)
(As of 03/28/2024 ET)
Today's Range
$3.91
$5.37
50-Day Range
$1.76
$5.01
52-Week Range
$1.61
$10.24
Volume
14.10 million shs
Average Volume
4.65 million shs
Market Capitalization
$508.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

Mesoblast MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
172.8% Upside
$13.67 Price Target
Short Interest
Healthy
0.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Mesoblast in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.71) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.03 out of 5 stars

Medical Sector

615th out of 938 stocks

Biological Products, Except Diagnostic Industry

100th out of 155 stocks

MESO stock logo

About Mesoblast Stock (NASDAQ:MESO)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MESO Stock Price History

MESO Stock News Headlines

Mesoblast Ltd LWB
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
MESO Jan 2025 0.500 call
MESO Oct 2024 2.000 call
MESO Jul 2024 2.000 put
Mesoblast Stock Rises 21% After FDA Feedback
See More Headlines
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/30/2023
Today
3/29/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.67
High Stock Price Target
$34.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+172.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-81,890,000.00
Net Margins
-1,061.43%
Pretax Margin
-1,094.53%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$6.16 per share

Miscellaneous

Free Float
82,446,000
Market Cap
$508.67 million
Optionable
Optionable
Beta
3.44
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 67)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
    Comp: $741.19k
  • Dr. Eric A. Rose M.D. (Age 73)
    Chief Medical Officer & Executive Director
    Comp: $627.54k
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Finance Officer
  • Mr. Peter T. Howard B.Sc. (Age 56)
    L.L.B., LLB (Hons), General Counsel & Corporate Executive
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster BSc (Age 47)
    M.B.A., MS, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., MMS, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing
  • Ms. Niva Sivakumar B.Com.
    L.L.B., Joint Company Secretary
  • Mr. Paul Hughes BPHARM
    Joint Company Secretary

MESO Stock Analysis - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings
or view top-rated stocks.

What is Mesoblast's stock price target for 2024?

6 brokerages have issued 1-year price targets for Mesoblast's shares. Their MESO share price targets range from $3.00 to $34.00. On average, they anticipate the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 172.8% from the stock's current price.
View analysts price targets for MESO
or view top-rated stocks among Wall Street analysts.

How have MESO shares performed in 2024?

Mesoblast's stock was trading at $2.20 on January 1st, 2024. Since then, MESO shares have increased by 127.7% and is now trading at $5.01.
View the best growth stocks for 2024 here
.

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 806,500 shares, an increase of 59.2% from the February 29th total of 506,600 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is presently 0.5 days.
View Mesoblast's Short Interest
.

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our MESO earnings forecast
.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) announced its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The company had revenue of $2.14 million for the quarter, compared to analysts' expectations of $2 million. Mesoblast had a negative trailing twelve-month return on equity of 16.32% and a negative net margin of 1,061.43%.

When did Mesoblast's stock split?

Shares of Mesoblast reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

Mesoblast (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a number of retail and institutional investors. Top institutional investors include Penbrook Management LLC (0.28%), Citadel Advisors LLC (0.00%), Affinity Asset Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MESO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners